ALK and neoplasm: This cohort includes patients with various tumor types harboring specific genetic alterations of MET or ALK, including MET amplification defined as a MET/CEP7 ratio of >2.2 (but not polysomy 7, kinase domain-activating mutations of MET, or other chromosomal translocations leading to altered transcriptional regulation of MET) as well as ALK chromosomal translocation or gene amplification.